Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole/escitalopram - Otsuka Pharmaceutical Development & Commercialization

Next Previous
Search
Drug Profile

Aripiprazole/escitalopram - Otsuka Pharmaceutical Development & Commercialization

Alternative Names: Escitalopram/aripiprazole; OPC-14597/escitalopram

Latest Information Update: 24 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Class Antidepressants; Antipsychotics; Benzofurans; Nitriles; Piperazines; Propylamines; Quinolines; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Serotonin 5-HT2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 13 Aug 2013 No development reported - Phase-III for Major depressive disorder (treatment-experienced) in USA, Australia, Bulgaria, Croatia, Estonia, Finland, France, Germany, Hungary, India, Mexico, Romania, Slovakia, South Korea, Spain and Taiwan (PO)
  • 15 Jul 2011 Otsuka terminates four phase III trials in Major depressive disorder (NCT01111539, NCT01111552, NCT01111565, NCT01123707)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top